Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1050 participants.
Also called NCT01949948
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,050 participants
- Sponsor
- Lars Thomassen
- Registry
-
NCT01949948
-
- Other papers using this trial's data
- Association between blood pressure and outcome in patients with acute ischemic stroke treated with alteplase
- Clinical outcomes and safety profile of Tenecteplase in wake-up stroke
- Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke
- Sex differences in the Norwegian Tenecteplase Trial (NOR-TEST)
- Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale
- Tenecteplase versus alteplase after acute ischemic stroke at high age
- Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT01949948. Randomized; double masking; primary purpose treatment. Start 2012-09 (actual); primary completion 2016-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
- Acronym
- NOR-TEST
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Alteplase
- Lead sponsor
- Lars Thomassen
- Collaborator
- The Research Council of Norway
Record details
- Record id
cardio:ct-nct01949948- Content hash
f9d1dbfcd64b3e6ce09441fd9caf60e5edb87553d524c54d396f6e58d30cdb79